Results 251 to 260 of about 28,483 (297)
Some of the next articles are maybe not open access.
Expert Opinion on Investigational Drugs, 1997
Alteplase (recombinant human tissue type plasminogen activator, rt-PA) was identified as a naturally occurring plasminogen activator in 1975, cloned from a human melanoma cell line in 1981, introduced into clinical trials in 1982, and received a product licence for the treatment of acute myocardial infarction in 1986.
openaire +2 more sources
Alteplase (recombinant human tissue type plasminogen activator, rt-PA) was identified as a naturally occurring plasminogen activator in 1975, cloned from a human melanoma cell line in 1981, introduced into clinical trials in 1982, and received a product licence for the treatment of acute myocardial infarction in 1986.
openaire +2 more sources
Alteplase and Thrombectomy — Not a Bridge to Dismantle
New England Journal of Medicine, 2021In the past few years, thrombectomy — the removal of a thrombus under angiographic guidance — has become an accepted treatment for acute ischemic stroke caused by occlusion of a large cerebral vess...
openaire +3 more sources
Reteplase versus Alteplase for Acute Ischemic Stroke.
New England Journal of MedicineBACKGROUND Alteplase is the standard agent used in early reperfusion therapy, but alternative thrombolytic agents are needed. The efficacy and safety of reteplase as compared with alteplase in patients with acute ischemic stroke are unclear. METHODS We
Shuya Li+15 more
semanticscholar +1 more source
Journal of the American Medical Association (JAMA)
Importance Tenecteplase is a bioengineered variant of alteplase with greater fibrin specificity and a longer half-life, allowing single-bolus administration.
Xia Meng+10 more
semanticscholar +1 more source
Importance Tenecteplase is a bioengineered variant of alteplase with greater fibrin specificity and a longer half-life, allowing single-bolus administration.
Xia Meng+10 more
semanticscholar +1 more source
Tenecteplase vs Alteplase in Acute Ischemic Stroke Within 4.5 Hours
NeurologyBackground and Objectives The current European Stroke Organisation expedited recommendation on tenecteplase (TNK) for acute ischemic stroke (AIS) advocates that TNK 0.25 mg/kg can be used alternatively to alteplase (tissue plasminogen activator [TPA ...
L. Palaiodimou+13 more
semanticscholar +1 more source
Alteplase for ischaemic stroke
The Lancet, 2014Vasilis Kontis and colleagues in their study (Aug 2, p 427) provided much needed estimates of the potential to lower premature mortality of four main non-communicable diseases (NCDs) by addressing six risk factors. These factors are part of a larger set of targets and indicators defi ned in WHO’s NCD Global Monitoring Framework (GMF) to meet the 25×25 ...
openaire +3 more sources
Alteplase for the Treatment of Pulmonary Embolism
Advanced Emergency Nursing Journal, 2015Pulmonary embolism can present with a wide range of symptoms, from asymptomatic to cardiac arrest, making diagnosis challenging. Alteplase is a fibrinolytic that is indicated for the treatment of pulmonary embolism in intermediate- and high-risk patients.
Christopher A. Paciullo+1 more
openaire +3 more sources
Alteplase and tenecteplase: Applications in the peripheral circulation
Techniques in Vascular and Interventional Radiology, 2001Alteplase (t-PA), a recombinant analogue of human tissue plasminogen activator, became the first genetically engineered thrombolytic approved by the Food and Drug Administration in 1987 for acute myocardial infarction (AMI). In addition to AMI, alteplase is currently approved for the treatment of acute ischemic stroke and pulmonary embolism, and we ...
Koji Sugimoto+5 more
openaire +3 more sources
Neurology
BACKGROUND AND OBJECTIVES Early treatment with intravenous alteplase increases the probability of lytic-induced reperfusion in large vessel occlusion (LVO) patients.
V. Yogendrakumar+21 more
semanticscholar +1 more source
BACKGROUND AND OBJECTIVES Early treatment with intravenous alteplase increases the probability of lytic-induced reperfusion in large vessel occlusion (LVO) patients.
V. Yogendrakumar+21 more
semanticscholar +1 more source
Pharmacokinetics of alteplase in the treatment of ischaemic stroke
Expert Opinion on Drug Metabolism & Toxicology, 2012Alteplase is the only approved drug for thrombolysis in acute ischaemic stroke (AIS) after its initial use in acute myocardial infarction (AMI). Its role in functional recovery is time-dependent while its major adverse effect, intracranial haemorrhage, is dose-dependent.
Paul Acheampong, Gary A. Ford
openaire +3 more sources